XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Operating Activities    
Net loss $ (29,893) $ (8,184)
Adjustments to reconcile net loss to net cash from operating activities:    
Depreciation and amortization 18,536 12,407
Amortization of debt issuance costs 233 215
Accretion of interest income from short-term investments 36 (338)
Loss on Assertio Therapeutics divestiture 8,174 0
Recurring fair value measurements of assets and liabilities 34 15
Provisions for inventory 2,675 3,877
Stock-based compensation 2,290 2,615
Changes in assets and liabilities, net of acquisition:    
Accounts receivable (6,970) 7,750
Inventories 2,753 (5,271)
Prepaid and other assets (7,912) 3,150
Accounts payable and other accrued liabilities 7,014 (1,627)
Accrued rebates, returns and discounts 9,583 286
Net cash provided by operating activities 6,553 14,895
Investing Activities    
Assertio Therapeutics divestiture (8,174) 0
Proceeds from maturities of short-term investments 57,572 0
Purchases of short-term investments (59,273) (43,320)
Net cash used in investing activities (9,875) (43,320)
Financing Activities    
Payments related to the vesting and settlement of equity awards, net (180) (281)
Net cash used in financing activities (180) (281)
Net decrease in cash and cash equivalents (3,502) (28,706)
Cash and cash equivalents at beginning of year 50,588 73,441
Cash and cash equivalents at end of period 47,086 44,735
Supplemental Disclosure of Cash Flow Information    
Net cash (refunded) paid for income taxes (837) 1,384
Cash paid for interest $ 1,300 $ 1,300